When Antidepressants Haven’t Been Enough: Understanding Why Providers May Consider Spravato for Treatment-Resistant Depression at Allied Healthcare in North Canton

For millions of Americans living with depression, oral antidepressants represent the first line of defense – and for many, they work effectively. But what happens when you’ve tried multiple medications, adjusted dosages, and followed your provider’s recommendations faithfully, only to find that your symptoms persist? This experience, broadly referred to as treatment-resistant depression (TRD), can feel deeply discouraging. In 2026, however, the treatment landscape looks different than it did even a few years ago. Spravato treatment has emerged as an FDA-approved option specifically designed for individuals whose depression has not responded adequately to traditional antidepressant therapies. At Allied Healthcare in North Canton, Ohio, providers work with patients to determine whether this newer approach may be the right next step in their mental health journey.

This post takes a comparison-based look at traditional antidepressants and Spravato, examining how they differ in mechanism, delivery, timeline, and candidacy – so you can have a more informed conversation with your healthcare provider about your options.

Understanding Treatment-Resistant Depression and Why It Matters

Depression is not a one-size-fits-all condition, and neither is its treatment. While standard antidepressants – including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclics, and others – are effective for a significant portion of people, research consistently shows that a meaningful percentage of patients do not achieve adequate relief after trying two or more medications at appropriate doses and durations. This is the clinical threshold commonly used to define treatment-resistant depression.

For individuals in this category, the emotional toll extends beyond the depression itself. There’s often a compounding sense of frustration and hopelessness that comes from feeling like nothing is working. This is precisely the population that Spravato (esketamine nasal spray) was developed to serve – adults with major depressive disorder who have not responded sufficiently to at least two prior antidepressant trials.

The Scope of Treatment Resistance

Estimates suggest that roughly one-third of individuals with major depressive disorder may experience treatment resistance at some point in their care. That translates to millions of people nationwide who may benefit from exploring alternatives beyond conventional oral antidepressants. At Allied Healthcare, serving patients in North Canton and the surrounding areas of Ohio, the clinical team understands the complexity of these cases and the importance of offering evidence-based options like Spravato.

How Traditional Antidepressants Work – And Where They May Fall Short

To understand why providers may recommend Spravato, it helps to first understand how conventional antidepressants function and where their limitations lie.

Mechanism of Action

Most traditional antidepressants work by modulating levels of monoamine neurotransmitters – primarily serotonin, norepinephrine, and sometimes dopamine – in the brain. SSRIs, for example, block the reabsorption of serotonin, making more of it available in the synaptic space. SNRIs do the same for both serotonin and norepinephrine. These medications have been the backbone of depression treatment for decades and have helped countless individuals manage their symptoms effectively.

Common Limitations

Despite their widespread use and proven efficacy in many patients, traditional antidepressants carry some well-documented limitations:

• Delayed onset: Most oral antidepressants take four to eight weeks to reach full therapeutic effect, which can be a difficult waiting period for patients in significant distress.
• Trial-and-error process: Finding the right medication and dosage often requires multiple attempts, with each new trial adding weeks or months to the process.
• Side effects: Weight gain, sexual dysfunction, fatigue, and gastrointestinal issues are among the common side effects that may lead patients to discontinue their medication.
• Incomplete response: Even when a medication provides some improvement, residual symptoms may persist, affecting quality of life and daily functioning.

None of this is to suggest that traditional antidepressants are inadequate – they remain a critical component of depression care for many people. However, for those who have not found sufficient relief through these pathways, the conversation naturally turns to other options.

What Is Spravato and How Does It Differ from Traditional Antidepressants?

Spravato (esketamine) is a nasal spray approved by the FDA in 2019 for the treatment of treatment-resistant depression in adults. It is derived from ketamine and works through an entirely different neurochemical pathway than conventional antidepressants, which is a key distinction in understanding its potential role in care.

A Different Neurological Pathway

While traditional antidepressants primarily target the monoamine system (serotonin, norepinephrine, dopamine), Spravato acts on the glutamate system – specifically the NMDA (N-methyl-D-aspartate) receptor. Glutamate is the most abundant excitatory neurotransmitter in the brain and plays a central role in synaptic plasticity and neural connectivity. By modulating this system, Spravato may help restore synaptic connections in brain circuits involved in mood regulation, potentially offering relief through a mechanism that monoamine-based medications do not address.

This fundamental difference in how the two types of treatment interact with brain chemistry is one reason why spravato treatment may be effective for patients whose depression has not responded to medications targeting serotonin and norepinephrine alone.

Onset of Effect

One of the most notable differences in comparing Spravato to traditional antidepressants is the timeline. While oral antidepressants typically require weeks to build up to therapeutic levels, some patients undergoing spravato treatment have reported noticing changes in their symptoms within hours to days of their initial sessions. It is important to note that individual responses vary, and Spravato is not a guaranteed rapid-acting solution for every patient. However, the potential for a faster onset of action is a meaningful point of differentiation, particularly for individuals who have been struggling with persistent symptoms for extended periods.

Comparing the Treatment Experience: Oral Antidepressants vs. Spravato

Beyond the science, the day-to-day experience of each treatment approach differs significantly. Understanding these practical distinctions can help patients set appropriate expectations.

Administration and Setting

Traditional antidepressants are taken orally at home, typically once or twice daily. They require minimal clinical oversight once prescribed, though regular follow-up appointments are recommended to monitor progress and side effects.

Spravato, by contrast, is administered as a nasal spray in a certified healthcare setting. At Allied Healthcare in North Canton, patients self-administer the spray under the supervision of trained clinical staff. Following each session, patients are monitored for a minimum of two hours due to potential temporary side effects such as dissociation, dizziness, nausea, or sedation. Patients are not permitted to drive on the day of treatment.

Treatment Schedule

The Spravato protocol typically follows a structured schedule:

• Induction phase (weeks 1–4): Sessions are generally scheduled twice per week.
• Maintenance phase (weeks 5–8): Sessions typically reduce to once per week.
• Ongoing maintenance (week 9 and beyond): Sessions may be spaced to once every one to two weeks, based on individual response and provider assessment.

This is a more time-intensive commitment compared to taking a daily pill, but for patients dealing with treatment-resistant depression, the structured clinical support and monitoring may offer added value and reassurance.

Use Alongside Other Treatments

An important point of comparison: Spravato is prescribed in conjunction with an oral antidepressant, not as a standalone replacement. This means patients continue taking their current antidepressant medication while adding Spravato to their regimen. Traditional antidepressants and spravato treatment are designed to work together, complementing each other through their distinct mechanisms of action.

Who May Be a Candidate for Spravato at Allied Healthcare?

Not everyone with depression is a candidate for Spravato. The treatment is specifically indicated for adults with major depressive disorder who have tried and not responded adequately to at least two different antidepressant medications in the current depressive episode. It is also approved for depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior, under appropriate clinical supervision.

Factors Providers Consider

When evaluating whether a patient may benefit from Spravato, providers at Allied Healthcare take a comprehensive approach, considering factors such as:

• The patient’s full medication history, including specific antidepressants tried, dosages, and duration
• The severity and duration of current depressive symptoms
• Any co-occurring medical or psychiatric conditions
• The patient’s ability to commit to the required treatment schedule and in-office monitoring
• Potential contraindications, including certain vascular conditions or a history of substance use disorders

A thorough clinical evaluation is essential to determine whether spravato treatment aligns with an individual’s specific needs and health profile. The team at Allied Healthcare encourages anyone considering this option to schedule a consultation to discuss their history and explore whether this approach may be appropriate.

Insurance Coverage

Allied Healthcare accepts a number of major insurance providers for Spravato services, including Aetna, Aultcare, Anthem, Blue Cross Blue Shield, Cigna, Medical Mutual of Ohio, United Healthcare/Oxford, and SummaCare. Patients are encouraged to reach out to the clinic directly to confirm their specific coverage details.

A Side-by-Side Summary

To consolidate the comparison, here is a high-level overview of how traditional oral antidepressants and Spravato differ across key dimensions:

• Mechanism: Traditional antidepressants target monoamine neurotransmitters (serotonin, norepinephrine); Spravato targets the glutamate/NMDA receptor system.
• Administration: Oral daily medication at home vs. supervised nasal spray in a clinical setting.
• Onset: Traditional antidepressants typically require 4–8 weeks; Spravato may produce noticeable changes in a shorter timeframe for some patients.
• Candidacy: Traditional antidepressants are first-line treatment for depression; Spravato is specifically indicated for treatment-resistant cases.
• Monitoring: Periodic follow-ups for oral medications; mandatory two-hour in-office observation after each Spravato session.
• Combination: Spravato is used alongside an oral antidepressant, not as a replacement.

Moving Forward When Standard Treatment Has Not Been Enough

Living with treatment-resistant depression is a challenging experience, and it is entirely understandable to feel uncertain about next steps after multiple unsuccessful medication trials. The emergence of Spravato as an FDA-approved option has offered a new pathway for patients who had previously exhausted conventional approaches. While it is not the right fit for every individual, and results vary from person to person, the clinical evidence supporting its use continues to grow in 2026.

At Allied Healthcare in North Canton, Ohio, the clinical team is committed to working with patients to evaluate all appropriate options, including spravato treatment, within a supportive and medically supervised environment. If you or a loved one has been managing depression that has not responded to traditional antidepressants, a consultation with a qualified provider may help clarify whether this treatment pathway could be a meaningful addition to your care plan.

To learn more about Spravato and whether it may be appropriate for your situation, contact Allied Healthcare to schedule a consultation. The team is here to answer your questions, review your treatment history, and help you explore the options available to you.